Patients with grade 1 endometrioid carcinomas, hormone receptor positivity, small focal lesions < 2 cm, in the absence of myometrial, adnexal, and lymphovascular space involvement, show an excellent prognosis, with a 5-year survival rate of 95%. This evidence concerns the gene NR4A1 and endometrioid adenocarcinoma.